2024-2029 Cuba Blood Typing, Grouping and Infectious Disease NAT Screening Market--2024 Supplier Shares and Strategies, 2024-2029 Volume and Sales Segment Forecasts for over 40 Individual Immunohematology and NAT Assays

December 2024 | - | ID: 26D1E22F20A3EN
Venture Planning Group

Abstracts

This unique report from LeadingMarketResearch.com provides information and analysis not available from any other published source.The report is available by section, and can be customized to specific information needs and budget.The database from LeadingMarketResearch.com provides the 2024 supplier shares and strategies, the 2024-2029 volume and sales forecasts for over 40 immunohematology and NAT assays, as well as comprehensive lists of companies developing or marketing new technologies and products by test, including:
Blood Typing and Grouping Tests
ABO, Antibody Panels, Antibody Screening/Indirect Antiglobulin, Antigen Typing (C, c, Duffy, E, e, I, i, Kell, Kidd, Le a, b, MN, P, S, s), Antiglobulin (Direct, C3 + IgG, IgG, C3), Crossmatching (Immediate Spin, Full Crossmatch), Rh (D, Du)
Infectious Disease Screening Tests
AIDS (HIV NAT, HIV-1/2), Cytomegalovirus, Hepatitis (HAV NAT, HBV NAT, HBs Ag, Anti-HBc, HCV NAT, HCV, ALT/SGPT), HTLV-I/II, Parvovirus B19 NAT, Syphilis, West Nile Virus NATThe companies analyzed in the report include:
Abbott
Beckman Coulter/Danaher
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Diagast
DiaSorin
Fujirebio
Grifols
Hologic
Immucor
LabCorp
Proteome Sciences
Quest Diagnostics
QuidelOrtho
Roche
Siemens Healthineers
Tecan
Thermo Fisher